Drugs / Fluzoparib
Fluzoparib
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | EU (EMA) | Wevdury | castration-resistant prostate carcinoma | 2026-10-09 | “欧洲药品管理局（EMA）已确认受理氟唑帕利胶囊” hengrui.com ↗ |
| Filed | China (NMPA) | 艾瑞颐 | castration-resistant prostate carcinoma | 2025-10-30 | “氟唑帕利胶囊（艾瑞颐 ® ）的药品上市许可申请获受理” hengrui.com ↗ |
Trials 97 · started per year
today
1
3
3
2
10
13
12
7
20
14
7
5
2015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 123 trials | ||||||
| Phase 1 | NCT05440006 | Jul 2022 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05032235 | Nov 2021 → Dec 2023 | impaired renal function disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04718740 | Jun 2021 → Oct 2022 | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04694365 | Mar 2021 → Jun 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04425876 | Dec 2020 → Mar 2023 | malignant pancreatic neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04333134 | Apr → May 2020 | — | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04341077 | Apr 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04108247 | Sep 2019 → Jun 2023 | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04041011 | Sep 2019 → Apr 2021 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04108676 | Sep 2019 | neoplastic disease or syndrome | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04011124 | Jul → Sep 2019 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04193319 | Jul → Sep 2019 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04013048 | Jul → Dec 2019 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03645200 | Jul → Dec 2019 | cancer of unknown primary site | Tianjin Medical University Second Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03945604 | Jun 2019 → Feb 2021 | triple-negative breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03509636 | Apr 2018 → Aug 2019 | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03182673 | Jul 2017 → Jun 2019 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03075462 | Mar 2017 → Aug 2021 | ovarian cancer, triple-negative breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03026881 | Jan 2017 → Apr 2018 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03062982 | Dec 2016 → Jan 2017 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02747342 | Sep 2016 → Jun 2019 | prostate cancer | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02759666 | Jun 2016 → Mar 2019 | neoplasm | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02575651 | Apr 2015 → Jun 2018 | high grade malignant neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT07141771 | Dec 2025 → Jun 2030 expected | small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06208410 | Jan 2024 → Feb 2027 expected | neoplasm | Risen (Suzhou) Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05983237 | Aug 2023 → Dec 2026 expected | melanoma | Jun Guo | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05928780 | Jul 2023 → Mar 2024 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04518501 | Jul 2020 → Dec 2024 overdue | — | Xing Xie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04659785 | Jul 2020 → Jul 2021 | small cell lung carcinoma | Tianjin Medical University Second Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04400188 | Jun 2020 → Jan 2022 | small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04228601 | Jan 2020 → Aug 2022 | pancreatic neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03805399 | Oct 2018 → Dec 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 251 trials | ||||||
| Phase 2 | NCT07647653 | Jun 2026 → Feb 2031 expected | ovarian cancer | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07353437 | Mar 2026 → Dec 2031 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07382713 | Feb 2026 → Dec 2030 expected | ovarian cancer | Jinhua Zhou | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07321015 | Jan 2026 → Nov 2027 expected | triple-negative breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07339553 | Jan 2026 → Jan 2029 expected | ovarian carcinoma | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07355010 | Dec 2025 → Dec 2028 expected | ovarian cancer | Qinglei Gao | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07047066 | Jul 2025 → Jul 2026 overdue | glioblastoma | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07033819 | Jun 2025 → Jun 2027 expected | ovarian carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06827717 | Apr 2025 → Apr 2027 expected | Ewing sarcoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06971211 | Nov 2024 → Oct 2027 expected | castration-resistant prostate carcinoma | Jianbin Bi | Recruiting | No outcome recorded |
| Phase 2 | NCT06735326 | Nov 2024 → Aug 2026 overdue | fallopian tube cancer, ovarian cancer, peritoneum cancer | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 2 | NCT06552858 | Sep 2024 → Sep 2026 overdue | ovarian cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06561022 | Aug 2024 → Dec 2025 overdue | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06541314 | Jun 2024 → May 2026 | ovarian cancer | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 2 | NCT06446206 | Jun 2024 → Jun 2026 overdue | — | The First Hospital of Jilin University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06413992 | May 2024 → Jun 2026 overdue | endometrial carcinoma, metastatic carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06254066 | Apr 2024 → Sep 2026 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06161272 | Dec 2023 → Mar 2025 | fallopian tube cancer, ovarian serous adenocarcinoma, primary peritoneal carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT06055166 | Nov 2023 → Nov 2024 | — | Chongqing University Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06081595 | Oct 2023 → Dec 2024 overdue | — | Jin Li | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06063070 | Oct 2023 → Jan 2025 overdue | fallopian tube cancer, ovarian endometrioid adenocarcinoma, ovarian serous adenocarcinoma, primary peritoneal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06145308 | Aug 2023 → Jul 2028 expected | salivary gland carcinoma | Peking Union Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT05753826 | Aug 2023 → Dec 2025 overdue | ovarian cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05585281 | Jul 2023 → Nov 2025 | ovarian cancer | Yongpeng Wang | Unknown | No outcome recorded |
| Phase 2 | NCT05952128 | Jul 2023 → Dec 2024 | sarcoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05932264 | Jul 2023 → Jul 2024 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05894018 | Jun 2023 → Dec 2028 expected | soft tissue sarcoma | Fujun Zhang | Recruiting | No outcome recorded |
| Phase 2 | NCT06516445 | Jun 2023 → Jun 2025 overdue | colorectal cancer | Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT06074692 | Jun 2023 → Aug 2026 overdue | bone sarcoma, soft tissue sarcoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05938374 | May 2023 → Dec 2024 | soft tissue sarcoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT05819060 | Apr 2023 → Sep 2024 | ovarian cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05834582 | Apr 2023 → Jun 2025 | triple-negative breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05732129 | Mar → Nov 2023 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05759546 | Feb 2023 → Nov 2025 overdue | breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05594095 | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05656131 | Nov 2022 → Mar 2026 | Her2-receptor negative breast cancer | wang shusen | Suspended | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05576389 | Oct 2022 → Apr 2024 overdue | Her2-receptor negative breast cancer | Peking University People's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05349409 | Jun 2022 → Nov 2024 | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05761470 | May 2022 → Jun 2024 overdue | Her2-receptor negative breast cancer | Ying Lin | Recruiting | No outcome recorded |
| Phase 2 | NCT05170594 | Dec 2021 → Jun 2024 | ovarian cancer | The Second Affiliated Hospital of Shandong First Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT04978012 | Jul 2021 → Dec 2024 | nasopharyngeal carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04869488 | Jul 2021 → Feb 2023 | metastatic prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04937972 | Jul 2021 → Dec 2024 | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05223582 | May 2021 → Dec 2023 | prostate cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04828395 | Mar 2021 → Mar 2023 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05085626 | Feb 2021 → Oct 2023 | Her2-receptor negative breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04535687 | Dec 2020 → Jun 2023 | renal cell carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 2 | NCT04355858 | May 2020 → May 2023 | breast cancer, metastatic malignant neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05406999 | Feb 2020 → Dec 2026 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT04102124 | Apr 2019 → Aug 2021 | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 312 trials · 3 met primary | ||||||
| Phase 3 | NCT06913777 | Apr 2025 → Oct 2026 expected | — | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06188455 | Dec 2024 → Dec 2025 overdue | ovarian cancer | The First Affiliated Hospital of Xiamen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06539091 | Oct 2024 → Oct 2025 overdue | malignant epithelial tumor of ovary | Anhui Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06612814 | Sep 2024 → Oct 2027 expected | breast carcinoma | Zhimin Shao | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06533384 | Aug 2024 → Dec 2026 expected | triple-negative breast carcinoma | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06255392 | Jun 2024 → Mar 2031 expected | Her2-receptor negative breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05891093 | Jun 2023 → May 2028 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT04691804 | Mar 2021 → Dec 2026 expected | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | Met primary |
| Phase 3 | NCT04300114 | Aug 2020 → Feb 2022 | malignant pancreatic neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT04296370 | Jul 2020 → Jun 2022 | Her2-receptor negative breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | Met primary |
| Phase 3 | NCT04229615 | Jun 2020 → Jun 2023 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03863860 | Apr 2019 → Jan 2022 | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT07000344 | Jul 2025 → Mar 2026 | ovarian cancer | Peking Union Medical College Hospital | Terminated | No outcome recorded |
| — | NCT04782089 | May 2021 → May 2023 | small cell lung carcinoma | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT05479487 Comparator | Aug 2022 → Nov 2023 overdue | — | Xiaohua Wu MD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04517357 Comparator | Oct 2020 → Nov 2023 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06954584 Background | May 2025 → May 2030 expected | ovarian cancer | Tongji Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-10-09 | Jiangsu HengRui Medicine Co., Ltd. | Regulatory 恒瑞医药创新药氟唑帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌适应症上市申请获欧洲药品管理局（EMA）受理 hengrui.com ↗
近日，恒瑞医药宣布欧洲药品管理局（EMA）已确认受理氟唑帕利胶囊（Wevdury ® ,中文商品名：艾瑞颐 ® ）的上市许可申请（Marketing Authorisation Application，简称“MAA”），申请的适应症为 联合醋酸阿比特龙和泼尼松或泼尼松龙用于治疗转移性去势抵抗性前列腺癌（mCRPC）成年患者 。 |
| 2026-06-02 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 ASCO口头报告｜恒瑞创新药氟唑帕利联合AA-P一线治疗转移性去势抵抗性前列腺癌期中分析结果重磅发布 hengrui.com ↗
研究结果显示，氟唑帕利联合AA-P组较安慰剂联合AA-P组显著延长rPFS（中位rPFS 24.8个月 [95% CI：20.4-30.4] vs. 19.9个月 [95% CI：15.2-22.2]；HR 0.71 [95% CI：0.55-0.91]；单侧p=0.0034），达到了主要研究终点。 |
| 2025-12-17 | Jiangsu HengRui Medicine Co., Ltd. | Results 中国智慧·世界看见｜恒瑞医药创新药氟唑帕利卵巢癌FZOCUS-1研究登顶全球肿瘤学顶级期刊 hengrui.com ↗
研究证实 1 ，以氟唑帕利为基础的维持治疗可以带来显著的生存获益。 |
| 2025-10-30 | Jiangsu HengRui Medicine Co., Ltd. | Regulatory 恒瑞创新药氟唑帕利胶囊前列腺癌新适应症上市申请获受理 hengrui.com ↗
近日，恒瑞医药收到国家药品监督管理局下发的《受理通知书》，公司自主研发的1类新药氟唑帕利胶囊（艾瑞颐 ® ）的药品上市许可申请获受理，适应症为： 本品联合阿比特龙和泼尼松或泼尼松龙用于DNA修复基因缺陷阳性（DRD+）的转移性去势抵抗性前列腺癌的一线治疗 。 |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-09 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞医药创新药氟唑帕利联合阿比特龙治疗转移性去势抵抗性前列腺癌适应症上市申请获欧洲药品管理局（EMA）受理 hengrui.com ↗ |
| 2026-06-02 | Jiangsu HengRui Medicine Co., Ltd. | 2026 ASCO口头报告｜恒瑞创新药氟唑帕利联合AA-P一线治疗转移性去势抵抗性前列腺癌期中分析结果重磅发布 hengrui.com ↗ |
| 2025-12-17 | Jiangsu HengRui Medicine Co., Ltd. | 中国智慧·世界看见｜恒瑞医药创新药氟唑帕利卵巢癌FZOCUS-1研究登顶全球肿瘤学顶级期刊 hengrui.com ↗ |
| 2025-10-30 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞创新药氟唑帕利胶囊前列腺癌新适应症上市申请获受理 hengrui.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 102 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzoparib | “Fluzoparib: 100 mg orally twice daily, with a 4-week continuous treatment cycle.” NCT07000344 ↗81“Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.” NCT05406999 ↗ “A single oral dose of fluzoparib on Day 1” NCT04341077 ↗ “fluzoparib 150 mg PO bid” NCT06145308 ↗ “SHR-1701 +fluzoparib” NCT04937972 ↗ |
| Known as | Fluzoparib Capsules | “Drug: Fluzoparib Capsules” NCT06188455 ↗ |
| Known as | fuzuloparib | “Phase 2: Zeprumetostat Tablets in Combination with Fuzuloparib Dose: Zeprumetostat Tablets 250 mg, bid, po, Fuzuloparib 100 mg, bid, po.” NCT07339553 ↗9“fuzuloparib (formerly fluzoparib) versus placebo as a maintenance treatment” PMID 35404684 ↗ Apr 2022 |
| Known as | Fuzuopali | ChEMBL registry synonym — accepted as the source's own label CHEMBL3930624 ↗ |
| Known as | HS-10160 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3930624 ↗ |
| Known as | SHR-3162 | “Drug Fluzoparib 100mg bid PO qd, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle.
Other names: SHR-3162” NCT05952128 ↗12“Drug Fluzoparib 50mg PO bid, administered continuously until disease progression, unacceptable toxicity or death. 28 days as a treatment cycle. Other names: SHR-3162.” NCT06827717 ↗ “A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer” NCT04400188 ↗ “A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients” NCT04041011 ↗ “she will receive PARP inhibitor SHR3162 150mg bid” NCT03805399 ↗ |
| Action | Inhibit | “PARP-1 and PARP-2 inhibitor” NCT02575651 ↗ |
| Modality | Small molecule | “Fluzoparib (SHR-3162) is an orally available, small molecule inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 1/2 being developed for treatment of...” NCT03509636 ↗ |
| Route | Oral | “when given orally to Chinese patients with advanced solid malignancies” NCT02575651 ↗ |